Mazor CEO Ori Hadomi discussed the company’s recent success with Globes: Israel’s Business Arena. He reported Mazor has met its targets under the agreement faster than expected, and he isn’t concerned they’ll miss any of the milestones that would prevent Medtronic from extending the contract between the two.
“Even if we meet the milestone, the decision is still completely up to Medtronic,” Mr. Hadomi said in the report. “I don’t want to speak for Medtornic, but I will be surprised if it doesn’t exercise the option before the deadline.” The deadline is February 2018.
Hospitals with Mazor’s original Renaissance robotic spine surgery system can trade in for the upgraded Mazor X, which has a shorter selling cycle: six to eight months, compared to one year.
More articles on orthopedic devices:
Mazor Q1 revenue jumps 83% with 12 Mazor X orders: 6 key notes
4 industry leaders comment on medical device tax
10 orthopedic device company CEOs: Who is paid the most?
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
